#3. #1 and #2 #4. limit #3 to human.
#5. limit #4 to (controlled clinical trial) #6. limit #5 to yr="2000.1-2019.5" Supplementary Table 2 . The revised and validated version of MINORS Methodological items for non-randomized studies Score* 1. A clearly stated aim: the question addressed should be precise and relevant in the light of available literature.
Inclusion of consecutive patients:
all patients potentially fit for inclusion (satisfying the criteria for inclusion) have been included in the study during the study period (no exclusion or details about the reasons for exclusion).
3. Prospective collection of data: data were collected according to a protocol established before the beginning of the study.
4.
Endpoints appropriate to the aim of the study: unambiguous explanation of the criteria used to evaluate the main outcome which should be in accordance with the question addressed by the study. Also, the endpoints should be assessed on an intention-to-treat basis.
5.
Unbiased assessment of the study endpoint: blind evaluation of objective endpoints and double-blind evaluation of subjective endpoints. Otherwise the reasons for not blinding should be stated. 8. Prospective calculation of the study size: information of the size of detectable difference of interest with a calculation of 95% confidence interval, according to the expected incidence of the outcome event, and information about the level for statistical significance and estimates of power when comparing the outcomes.
Follow

Additional criteria in the case of comparative study
9. An adequate control group: having a gold standard diagnostic test or therapeutic intervention recognized as the optimal intervention according to the available published data.
Contemporary groups:
control and studied group should be managed during the same time period (no historical comparison).
Baseline equivalence of groups:
the groups should be similar regarding the criteria other than the studied endpoints. Absence of confounding factors that could bias the interpretation of the results.
Adequate statistical analyses:
whether the statistics were in accordance with the type of study with calculation of confidence intervals or relative risk.
*The items are scored 0 (not reported), 1 (reported but inadequate) or 2 (reported and adequate). Study selection 5-6 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
Supplementary
Page 5-6 (Data extraction and quality assessment, Supplementary  Table 2) Data collection process 5-6 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
Page 5-6 (Data extraction and quality assessment, Supplementary  Table 2) Data items 6 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
Page 6 (Outcome definition)
Risk of bias in individual studies
5-6 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
Page 5-6 (Data extraction and quality assessment, Supplementary 
Section/topic # Checklist item Reported on page #
Risk of bias across studies 6-7 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
Page 6-7 (Statistical analysis)
Additional analyses 6-7 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
RESULTS
Study selection 7 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
Page 7 (Search results, Fig 2) Study characteristics 7-8 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. Fig 4-9 , Supplementary  Fig 1 and 2) Risk of bias across studies 10-11 Present results of any assessment of risk of bias across studies (see Item 15). Page 10-11 (Publication bias, Fig 10) Additional analysis 12 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).
Page 12 (Sensitivity analysis, Table  3 )
DISCUSSION
Summary of evidence 11-14 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
Page 11-14 (Discussion)
Limitations 13-14 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). For more information, visit: www.prisma-statement.org.
